Sipuleucel-T (Provenge®)—Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention

Published 2015 View Full Article

Authors

Keywords

Chief Executive Officer, Abiraterone, Enzalutamide, Abiraterone Acetate, Convertible Debt

Journal

BIODRUGS

Volume 29, Issue 5, Pages 301-307

Publisher

Springer Nature

Online

2015-09-24

DOI

10.1007/s40259-015-0140-7

References

View 12 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started